Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 566 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Vaginal Diseases Clear all

Conditions: HIV Infections
Interventions: Tenofovir gel; Drug
Lead sponsor: CONRAD; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Houston, Texas

Conditions: Gynecologic Neoplasm, Brachytherapy, Therapeutic Touch, Endometrial Cancer, Cervical Cancer, Vaginal Cancer, Vulvar Cancer
Interventions: Reiki therapy; Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Premature Birth
Interventions: Vaginal Progesterone, Intramuscular Progesterone (17 alpha hydroxprogesterone caproate); Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Springfield, Massachusetts • Philadelphia, Pennsylvania

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Uterine Neoplasms, Endometrial Cancer, Vaginal Cancer, Vulvar Cancer, Cervical Cancer
Interventions: Not listed
Lead sponsor: Precision Therapeutics; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 2,756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 67
States / cities: Birmingham, Alabama • Mobile, Alabama • San Francisco, California + 59 more

Conditions: Labor, Premature
Interventions: cervical cerclage; Procedure
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 16 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Menopause, Vulvovaginal Atrophy, Painful Intercourse, Dyspareunia
Interventions: Estradiol, placebo; Drug
Lead sponsor: TherapeuticsMD; Industry
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: DeLand, Florida

Conditions: Vaginal Inflammation, Vaginal Infections
Interventions: Imiquimod, Placebo, Nonoxynol-9; Drug · Other
Lead sponsor: CONRAD; Other
Eligibility: 21 Years to 45 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Dyspareunia
Interventions: Estradiol, Imvexxy, Placebo; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 1,050 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 42
States / cities: Birmingham, Alabama • Chandler, Arizona • Sacramento, California + 36 more

Conditions: Vulvovaginal Candidiasis (VVC), Yeast Vaginitis
Interventions: vaginal cooling device; Device
Lead sponsor: Coologics, Inc; Industry
Eligibility: 22 Years to 49 Years · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 10
States / cities: Jacksonville, Florida • Miami, Florida • Smyrna, Georgia + 7 more

Conditions: Pelvic Radiotherapy, Vaginal Stenosis, Pelvic Cancer, Gynecologic Cancers, Anorectal Cancer, Urologic Cancer
Interventions: Improving Engagement with Vaginal Dilator Therapy after Pelvic Radiation; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Recurrent Urinary Tract Infection
Interventions: Conjugated Estrogen Vaginal Cream, Estradiol Ring, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: La Jolla, California • New York, New York

Conditions: Visceral Prolapse
Interventions: Open, Robotic, or Laparoscopic, Transvaginal Native Tissue Repair, Uphold™ LITE; Procedure
Lead sponsor: NICHD Pelvic Floor Disorders Network; Network
Eligibility: 21 Years and older · Female only
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 10
States / cities: Birmingham, Alabama • San Diego, California • Albuquerque, New Mexico + 6 more

Conditions: Cancer
Interventions: trastuzumab, tipifarnib; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 2
States / cities: Fort Sam Houston, Texas • San Antonio, Texas

Conditions: Stress Urinary Incontinence
Interventions: Tension-free vaginal tape obturator system; Device
Lead sponsor: Ethicon, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 11
States / cities: Denver, Colorado • Norwalk, Connecticut • Louisville, Kentucky + 8 more

Conditions: Human Immunodeficiency Virus
Interventions: Dapivirine Vaginal Ring, Placebo Vaginal Ring; Drug
Lead sponsor: International Partnership for Microbicides, Inc.; Industry
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Birmingham, Alabama • Cleveland, Ohio • Pittsburgh, Pennsylvania

Conditions: GBS Positive, Women in Labor Given Vancomycin for Prophylaxis
Interventions: Not listed
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years to 48 Years · Female only
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer, Brain Tumor, Glioblastoma, Astrocytoma, Bile Duct Cancer, Cholangiocarcinoma, Bladder Cancer, Bone Cancer, Synovial Sarcoma, Chondrosarcoma, Liposarcoma, Sarcoma, Kaposi, Sarcoma,Soft Tissue, Sarcoma, Osteosarcoma, CNS Cancer, Brain Stem Neoplasms, Breast Cancer, Cervical Cancer, Colorectal Cancer, Rectal Cancer, Colon Cancer, Esophageal Cancer, Esophagus Cancer, Cancer of Colon, Pancreatic Cancer, Cancer of Pancreas, Testis Cancer, Testicular Cancer, Ureter Cancer, Renal Cell Carcinoma, Kidney Cancer, Gestational Trophoblastic Tumor, Head and Neck Neoplasms, Parotid Tumor, Larynx Cancer, Tongue Cancer, Pharynx Cancer, Salivary Gland Cancer, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Multiple Myeloma, Non Hodgkin Lymphoma, Carcinoid Tumor, Lung Cancer, Neuroendocrine Tumors, Mesothelioma, Thyroid Cancer, Parathyroid Neoplasms, Adrenal Cancer, Small Bowel Cancer, Stomach Cancer, Liver Cancer, Hepatic Cancer, Melanoma, Skin Cancer, Unknown Primary Tumors, Uterine Cancer, Fallopian Tube Cancer, Ovarian Cancer, Prostate Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Waldenstrom Macroglobulinemia, Cancer, Advanced, Thymus Cancer, Nasopharyngeal Carcinoma, Multiple Endocrine Neoplasia, Pheochromocytoma, Small Cell Carcinoma, Pulmonary Carcinoma
Interventions: Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P); Diagnostic Test · Drug · Other
Lead sponsor: Taproot Health; Industry
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Idaho Falls, Idaho • Laredo, Texas

Conditions: Genitourinary System; Disorder, Female, Burning Vagina, Dyspareunia, Irritation; Vagina, Menopause Related Conditions, Urinary Incontinence, Urinary Bladder, Overactive, Urinary Tract Infections, Stress Urinary Incontinence
Interventions: fCO2 Laser Therapy Group; Device
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Trichomonas Vaginitis, Bacterial Vaginitis
Interventions: Metronidazole 500 mg, Secnidazole 2000 MG; Drug
Lead sponsor: Tulane University; Other
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 4
States / cities: Birmingham, Alabama • North Miami, Florida • New Orleans, Louisiana

Conditions: Health, Vulvovaginal Candidiasis
Interventions: Miconazole nitrate, Magnetic resonance imaging, Moderate levels of exercise; Drug · Procedure · Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Endometrial Cancer
Interventions: HDR vaginal brachytherapy; Radiation
Lead sponsor: Kara Romano, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 3
States / cities: Baltimore, Maryland • Syracuse, New York • Charlottesville, Virginia

Conditions: Preterm Labor, Preterm Contractions, Abdominal Cramping, Back Pain, Vaginal Pressure, Vaginal Bleeding
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: Female only
Enrollment: 589 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Vaginal Flora
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 15 Years to 44 Years · Female only
Enrollment: 5,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2010
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Allergic Diseases, Asthma
Interventions: Vaginal seeding, Placebo Seeding, Standard care, Post-seeding Care; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 2
States / cities: New York, New York

Search by objective public record fields.

Pharmacokinetic Study of the Vaginal Microbicide Agent 1% Tenofovir Gel

Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies

Vaginal Versus Intramuscular Progesterone for the Prevention of Recurrent Preterm Birth

ChemoFx® PRO - A Post-Market Data Collection Study

Ultrasound-indicated Cerclage to Prevent Premature Birth in High-risk Women

TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy

Identification of Novel Biomarkers of Cervicovaginal Mucosal Inflammation

Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy

Clinical Study of a Vaginal Cooling Device for the Treatment of Vulvovaginal Candidiasis (VVC)

Vaginal Dilator Therapy After Pelvic Radiation

Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women

Apical Suspension Repair for Vault Prolapse In a Three-Arm Randomized Trial Design

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

A Clinical Evaluation of the Tension-Free Vaginal Tape Obturator System For Treatment of Stress Urinary Incontinence (Urinary Leakage)

Safety and Pharmacokinetics of Dapivirine Vaginal Ring in Post-menopausal Women

Intrapartum Vancomycin for Group B Streptococcus (GBS) Prophylaxis

The Registry of Oncology Outcomes Associated With Testing and Treatment

Laser Therapy for Treatment of Urogenital Symptoms in Women

Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole

Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina

Vaginal Cuff Brachytherapy Fractionation Study

Screening To Obviate Preterm Birth

Longitudinal Study of Vaginal Flora

Vaginal Microbiome Exposure and Immune Responses in C-section Infants